An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.
Exploring the companies and themes that make up this emerging and exciting new sector
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
Psychedelics Investing 101: Basic Investing Tips
Psychedelic drugs are an emerging sector with exciting investment potential. Here are some tips on beginning your due diligence.
Numinus Positioned To Be Significant Player In Psilocybin R&D
Numinus Wellness Inc. has assembled the licensing and personnel to be a significant player in psilocybin-based drug research.
Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus
New psychedelics company specializing in psilocybin-based medical research has filed a prospectus.
MindMed Developing IP For Personalized Psychedelic Assisted Therapies
MindMed files patent applications for technologies to screen and optimize dosing of MDMA and LSD.
Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
Psychedelics micro-dosing offers several key advantages over psychedelic drug applications centered around heavier dosages.
ATAI Life Sciences Forges Premier Psychedelics R&D Platform
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.
Top Canadian Entrepreneur Michael Forbes Joins Board of Directors of PharmaDrug Inc.
PharmaDrug adds depth to its board with new Director who has a wealth of healthcare and addiction-therapy experience.
Champignon Announces Closing of $15 Million Bought Deal Private Placement
Champignon Brands closes on a $15 million financing to expand its clinical psychedelics research programs.
Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with University of Wisconsin-Madison
Revive expands on its psychedelics research aimed at addiction treatment.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.